-

09:07:39 PM

ABBV Stock News

ABBV - Abbvie Inc

06/27/22 8:00 AM

NYSE : ABBV

Approximately 15,000 AbbVie Employees to Volunteer Globally to Support Local Communities in Annual Week of Possibilities

– AbbVie's Week of Possibilities returns in 2022 for its seventh year with approximately 15,000 employees participating in volunteer activities globally to strengthen local communities, expand educational programs and make a positive environmental impact – Week of Possibilities is AbbVie's global,

RHEA-AI

very positive

06/27/22 2:00 AM

NYSE : ABBV

CHMP Recommends Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis

CHMP positive opinion is based on results from the Phase 3 SELECT-AXIS 2 study showing upadacitinib (RINVOQ ® ) met the primary endpoint of ASAS40 response at week 14 versus placebo 1 Non-radiographic axial spondyloarthritis (nr-axSpA) is part of the axial spondyloarthritis (axSpA) spectrum and

RHEA-AI

neutral

06/24/22 8:00 AM

NYSE : ABBV

New Survey Offers Perspective on Mental and Emotional Journey for Patients Diagnosed with Slow-Growing Blood Cancer

- New insights uncover how patients and caregivers cope emotionally during phases of Chronic Lymphocytic Leukemia (CLL) - The findings also show majority of HCPs view treating CLL patients as different from treating other cancers - The emotional complexities of this slow-growing cancer point to

RHEA-AI

neutral

06/23/22 3:43 PM

NYSE : ABBV

dividends

AbbVie Declares Quarterly Dividend

The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share.The cash dividend is payable August 15, 2022, to stockholders of record at the close of business on July 15, 2022.Since the company's

RHEA-AI

neutral

06/21/22 8:00 AM

NYSE : ABBV

AbbVie Submits Supplemental New Drug Application to U.S. FDA for Atogepant (QULIPTA™) to Support Label Expansion for the Preventive Treatment of Migraine

- Submission is based on pivotal Phase 3 PROGRESS chronic migraine study evaluating atogepant (QULIPTA TM) in adult patients that met primary endpoint of statistically significant reduction from baseline in mean monthly migraine days compared to placebo- If approved, atogepant (QULIPTA) would be

RHEA-AI

positive

06/17/22 9:00 AM

NYSE : ABBV

Allergan Aesthetics publishes 'The Future of Aesthetics' global trends report providing unrivalled insight into future of industry

Built on robust market research and analysis of global social listening data, industry research, academic studies, and Allergan Aesthetics*

RHEA-AI

very positive

06/17/22 8:00 AM

NYSE : ABBV

fda approval

SKYRIZI® (risankizumab-rzaa) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn's Disease in Adults

- Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn's disease, ADVANCE, MOTIVATE and FORTIFY 1-4- As early as week 4 in the induction

RHEA-AI

neutral

06/11/22 8:45 AM

NYSE : ABBV

clinical trial

AbbVie Announces Late-Breaking Results from Phase 2 Trial of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL) at the European Hematology Association (EHA) Annual Congress

– Epcoritamab shows clinically meaningful efficacy in challenging-to-treat, highly refractory LBCL patients – Total patient population achieved overall response rate (ORR) of 63 percent and complete response (CR) of 39 percent; CAR T-naïve patients achieved 69 percent ORR and 42 percent CR;

RHEA-AI

positive

06/10/22 3:15 AM

NYSE : ABBV

AbbVie Presents Investigational Navitoclax Preliminary Data in JAK Inhibitor Naïve Myelofibrosis Patients

Data is supportive of early intervention in myelofibrosis to achieve improved clinical outcomes in spleen volume reduction (SVR), symptom score, bone marrow fibrosis (BMF), and anemia Results are from an exploratory analysis of navitoclax plus ruxolitinib from Cohort 3 of the Phase 2 REFINE study

RHEA-AI

neutral

06/10/22 1:05 AM

NYSE : ABBV

New Data Demonstrates AbbVie's VENCLYXTO®/VENCLEXTA® Combination Sustained Progression-Free Survival in Chronic Lymphocytic Leukemia Patients After Four Years Off Treatment

Five-year follow-up analysis of the Phase 3 CLL14 trial (median follow-up of 65.4 months) continues to demonstrate longer progression-free survival (PFS) after fixed-duration venetoclax plus obinutuzumab compared to fixed-duration chlorambucil plus obinutuzumab in previously untreated patients with

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next